COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 8,461,540 shares of its common stock at a price of $1.30 per share, for aggregate gross proceeds of approximately $11.0 million, in a registered direct offering priced at-the-market under Nasdaq rules. H.C. Wainwright & Co. is acting as exclusive placement agent for the offering. This offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-220632) previously filed with the Securities and Exchange Commission (SEC).
Airlines, hotels, casinos and other stocks continue to fall as fear of the coronavirus grows worldwide and all but halts activity in the virus epicenter of Wuhan, China. Alpha Pro Tech, Ltd. (NYSE: APT) manufactures masks and protective apparel — goods already in high demand in China. Lakeland Industries, Inc. (NASDAQ: LAKE) also produces protective clothes for high-risk workers, such as the medical professionals and public health officials exposing themselves to patients.
Advancing preclinical COVID-19 Coronavirus program leveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) Continuing collaboration.
- Work completed over decades of renowned biochemist’s career serves as basis for Company’s structure-based technology which has demonstrated broad utility in development of.
H.C. Wainwright & Co. is acting as exclusive placement agent for the offering. This offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-220632) previously filed with the Securities and Exchange Commission (SEC). A final prospectus supplement and the accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov.
COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today the closing of its previously announced registered direct offering with several institutional investors for 8,461,540 shares of its common stock at a purchase price of $1.30 per share, priced at-the-market under Nasdaq rules. The gross proceeds to the Company from the offering totaled approximately $11.0 million, before deducting placement agent fees and offering expenses. The shares of common stock described above were offered by Cocrystal Pharma pursuant to a shelf registration statement on Form S-3 (No. 333-220632), which was previously declared effective by the Securities and Exchange Commission (“SEC”).
A live audio webcast of the presentation will be available on the IR Calendar page of the Investors section of the Company’s website (cocrystalpharma.com). Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs.
The gross proceeds to the Company from the offering totaled approximately $6.8 million, before deducting placement agent fees and offering expenses. The shares of common stock described above were offered by Cocrystal Pharma pursuant to a shelf registration statement on Form S-3 (No. 333-220632), which was previously declared effective by the Securities and Exchange Commission (“SEC”). A final prospectus supplement and the accompanying prospectus relating to the shares of common stock were filed by Cocrystal with the SEC and can be obtained at the SEC’s website at www.sec.gov.
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...
– Presentation on Tuesday, February 18th at 11:30 AM ET – BOTHELL, WA, Feb. 11, 2020 -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical.
Cocrystal Pharma, Inc (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced its financial results for the quarter ended March 31, 2020 and provided program updates. Entered into license agreement with Kansas State University Research Foundation (“KSURF”) to further develop certain proprietary broad-spectrum antiviral compounds for the treatment of norovirus and coronavirus infections (“COVID-19”). Entered into additional license agreement with KSURF to include rights to additional preclinical leads and further develop certain proprietary broad-spectrum antiviral compounds for the treatment of coronavirus infections.
Companies In The News Are: COCP, CGEN, AAPL, NINE
Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today that it has expanded its previously announced license agreement with Kansas State University Research Foundation (“KSURF”) to include rights to additional preclinical leads and further develop certain proprietary broad-spectrum antiviral compounds for the treatment of coronavirus infections (“COVID-19”). The additional compounds from this new license agreement represent a class of compounds called protease inhibitors to potentially treat COVID-19.
In 2016, Gary Wilcox was appointed CEO of Cocrystal Pharma, Inc. (NASDAQ:COCP). This report will, first, examine the...
Company has immediately initiated Coronavirus programLeveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) Strong financial.
The Company intends to use the net proceeds for working capital and other general corporate purposes. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering. This offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-220632) previously filed with the SEC.
BOTHELL, WA, Feb. 24, 2020 -- - Company acquires rights to preclinical leads for Norovirus and Coronavirus therapeutics - - Proprietary platform technology will be used.
– Positive preclinical and clinical data obtained to date in hepatitis C, influenza and norovirus programs bolster confidence in potential of our platform to address.
BOTHELL, WA, Feb. 03, 2020 -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel.
Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today provided an update on the impact of the COVID-19 global pandemic on its preclinical and clinical development programs. “We have reprioritized development activities to accelerate the advancement of our preclinical COVID-19 program, which we recently established as a result of our license agreements with Kansas State University Research Foundation (KSRF),” commented Dr. Gary Wilcox, Chairman and Chief Executive Officer of Cocrystal.